Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028
At a glance
- $OCUL today−3.22%last $6.01
- Vs industry peers−2.83 pts6-peer median −0.39% · far behind
- Since Nov 9−10.4%from the first trade after the story
- 52-week range1.2% above low$5.94 – $16.44
- Cash runway~24 mo$530.6M cash ÷ $22.2M/mo burn · 10-Q
- In the headline$530.6 millionAmount
- Key person: Filed with SEC
- Clear: legal, regulatory, security, operational, financial integrity
Early signals (1) — filed with the SEC or first reported, not yet widely covered
- Key person · SEC 8-K, Item 5.02, Nov 9: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.
What it means
- What to watch: The headline zeroes in on $530 — a single figure, but it's the lens through which the bigger picture gets refracted.
- How the stock is trading: $OCUL -3.22% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Ocular Therapeutix ($OCUL) slid 3.22% to $6.01 in the latest session. Over the past month it is down 4.5%. It now sits 63% under the 52-week high of $16.44 and 1.2% above the year's low of $5.94, close to the bottom of its range. It has been a volatile year: the high was 2.8 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 9, 2026), $OCUL lost $94.8M over the quarter to Sep 30, 2026 on revenue of $12.9M (-4.5% QoQ). Operations used $198.9M of cash over the nine months to Sep 30, 2026 — about $22.2M a month — against $530.6M in cash on Sep 30, 2026. At that pace the cash covers about 24 months. Total liabilities were $164.7M against $530.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 9, the same day as this story; it is $OCUL's own account and the first thing to read. Figures are as filed with the SEC; the $OCUL page has the full statements.
How much coverage it is getting
Wook has no other story on Ocular Therapeutix from the last 30 days, so there is no recent run to compare this one with.
The bigger picture
Earnings reports are less about the numbers and more about how they stack up against what was expected — and how the future looks from there. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The $OCUL page holds the full story — charts, filings, and models. Comparing coverage from different outlets is the fastest way to see if the story is being echoed or just echoed. Wook AI is here to help crunch the numbers, from past highs to this week’s chatter.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on November 9, 2026. $OCUL has moved -10.43% ($6.71 to $6.01). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
